Lilly’s Zepbound Now Available in Four-Dose KwikPen Priced at $299 Monthly
FDA approved label expansion allows Lilly’s Zepbound (tirzepatide) to be delivered via a four-dose KwikPen, offering a month’s treatment in a single device. Self-pay patients through LillyDirect can access Zepbound KwikPen or vials at $299 per month for the 2.5 mg dose, supporting over 1 million users in 2025.
1. FDA Approves Multi-Dose KwikPen for Zepbound
The U.S. Food and Drug Administration expanded Zepbound’s label to include a four-dose single-patient KwikPen, allowing patients to receive a full month of treatment in one reusable device. This approval aligns Zepbound with Lilly’s existing KwikPen platform, widely used for other injectable therapies.
2. Pricing and Access via LillyDirect
Patients with a valid prescription can opt for self-pay through LillyDirect, accessing all monthly doses in either KwikPen or single-dose vials at a starting price of $299 for the 2.5 mg dose. In 2025, LillyDirect served over 1 million users, with one in three new branded weight management patients choosing Zepbound self-pay vials.
3. Clinical Efficacy Highlights
In the SURMOUNT-1 trial, adults on Zepbound achieved an average weight loss of 20.9% over 72 weeks versus 3.1% for placebo. The SURMOUNT-5 open-label study showed average losses of 50 lb (20.2%) on Zepbound compared to 33 lb (13.7%) on Wegovy.
4. Market Impact and Prospects
As the top prescribed injectable obesity-management therapy of 2025, Zepbound’s KwikPen launch strengthens Lilly’s leadership in weight management. The device expansion and competitive pricing may drive further adoption and revenue growth in the growing obesity treatment market.